drugset / Trial / NCT00464269

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269

Phase 3 Completed 400 enrolled UCB Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.

Timeline

Start
2007-09
Primary completion
2008-12
Completion
2009-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 2.5 mg Oral
Subject Brivaracetam Small molecule 10 mg Oral
Subject Brivaracetam Small molecule 25 mg Oral

Indications